An integrated approach to the medical treatment of chronic obstructive pulmonary disease

Medical Clinics of North America

Volumn 96, Issue 4, 2012, Pages 811-826

  Rosenberg, Sharon R ^a   Kalhan, Ravi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chronic obstructive pulmonary disease (COPD); Lung function; Patient centered outcomes; Symptoms; Treatment

Indexed keywords

AZITHROMYCIN; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CLARITHROMYCIN; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; IPRATROPIUM BROMIDE; METHYLXANTHINE; MOXIFLOXACIN; PLACEBO; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ABDOMINAL PAIN; ANXIETY; APPETITE; BODY MASS; CHEST TIGHTNESS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COUGHING; CYSTIC FIBROSIS; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; ELECTROCARDIOGRAM; EXERCISE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HEALTH CARE PERSONNEL; HEALTH STATUS; HEARING DISORDER; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LUNG CANCER; LUNG FUNCTION; MEDICARE; MORTALITY; NAUSEA; OSTEOPOROSIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY REHABILITATION; QUALITY OF LIFE; REIMBURSEMENT; REVIEW; SEIZURE; SIDE EFFECT; SURGICAL MORTALITY; TOTAL LUNG CAPACITY; TREATMENT PLANNING; WALKING;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANTI-INFECTIVE AGENTS; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EXERCISE TEST; FORCED EXPIRATORY VOLUME; HUMANS; LUNG VOLUME MEASUREMENTS; MACROLIDES; MUSCARINIC ANTAGONISTS; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84863842032     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2012.05.002     Document Type: Review

References (90)

1. Kochanek K., Xu J., Murphy S., et al. Deaths: preliminary data for 2009 2011, National Center for Health Statistics, Hyattsville (MD).
2. NHLBI morbidity and mortality chart book. Available at: Accessed April 14, 2012. http://www.nhlbi.nih.gov/resources/docs/cht-book.htm.
3. Celli B.R., MacNee W., Agusti A., et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
4. Global strategy for the diagnosis, management and prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available at: Accessed April 14, 2012. http://www.goldcopd.org/.
5. Pauwels R.A., Buist A.S., Calverley P.M., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001, 163:1256-1276.
6. Mahler D.A., Harver A. A factor analysis of dyspnea ratings, respiratory muscle strength, and lung function in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992, 145:467-470.
7. Cooper C.B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006, 119:21-31.
8. Jones P.W. Issues concerning health-related quality of life in COPD. Chest 1995, 107:187S-193S.
9. Hurst J.R., Vestbo J., Anzueto A., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 363:1128-1138.
10. Nishimura K., Izumi T., Tsukino M., et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002, 121:1434-1440.
11. Mahler D.A. Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3:234-238.
12. Jones P.W., Harding G., Berry P., et al. Development and first validation of the COPD assessment test. Eur Respir J 2009, 34:648-654.
13. Dodd J.W., Hogg L., Nolan J., et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011, 66:425-429.
14. Dodd J.W., Marns P.L., Clark A.L., et al. The COPD assessment test (CAT): short- and medium-term response to pulmonary rehabilitation. COPD 2012, [Epub ahead of print].
15. Jones P.W., Harding G., Wiklund I., et al. Tests of the responsiveness of the chronic obstructive pulmonary disease (COPD) assessment test TM (CAT) following acute exacerbation and pulmonary rehabilitation. Chest 2012, [Epub ahead of print].
16. Mackay A.J., Donaldson G.C., Patel A.R., et al. Utility of the COPD assessment test (CAT) to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med 2012, 185(11):1218-1224.
17. Casanova C., Cote C., de Torres J.P., et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005, 171:591-597.
18. Ofir D., Laveneziana P., Webb K.A., et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I COPD. Am J Respir Crit Care Med 2008, 177:622-629.
19. Garcia-Rio F., Lores V., Mediano O., et al. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly associated with dynamic hyperinflation. Am J Respir Crit Care Med 2009, 180:506-512.
20. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166:111-117.
21. Pinto-Plata V.M., Cote C., Cabral H., et al. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 2004, 23:28-33.
22. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350:1005-1012.
23. Ong K.C., Earnest A., Lu S.J. A multidimensional grading system (BODE Index) as predictor of hospitalization for COPD. Chest 2005, 128:3810-3816.
24. Imfeld S., Bloch K.E., Weder W., et al. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006, 129:873-878.
25. Cote C.G., Celli B.R. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005, 26:630-636.
26. Pompeo E., Mineo T.C. Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients. Ann Thorac Surg 2007, 84:1862-1869. [discussion: 1862-9].
27. Puhan M.A., Garcia-Aymerich J., Frey M., et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009, 374:704-711.
28. Jones R.C., Donaldson G.C., Chavannes N.H., et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009, 180:1189-1195.
29. Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev 2010, 19:113-118.
30. Donaldson G.C., Wedzicha J.A. COPD exacerbations.1: epidemiology. Thorax 2006, 61:164-168.
31. Donaldson G.C., Seemungal T., Bhowmik A., et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002, 57:847-852.
32. Spencer S., Calverley P.M., Burge P.S., et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004, 23:698-702.
33. Cote C.G., Dordelly L.J., Celli B.R. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007, 131:696-704.
34. Wilkinson T.M., Donaldson G.C., Hurst J.R., et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004, 169:1298-1303.
35. Langsetmo L., Platt R.W., Ernst P., et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008, 177:396-401.
36. Vijayasaratha K., Stockley R.A. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008, 133:34-41.
37. Fabbri L.M., Luppi F., Beghe B., et al. Complex chronic comorbidities of COPD. Eur Respir J 2008, 31:204-212.
38. Ng T.P., Niti M., Tan W.C., et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007, 167:60-67.
39. Eisner M.D., Blanc P.D., Yelin E.H., et al. Influence of anxiety on health outcomes in COPD. Thorax 2010, 65:229-234.
40. Schroedl C., Kalhan R. Incidence, treatment options, and outcomes of lung cancer in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2012, 18:131-137.
41. Raviv S., Hawkins K.A., DeCamp M.M., et al. Lung cancer in chronic obstructive pulmonary disease: enhancing surgical options and outcomes. Am J Respir Crit Care Med 2011, 183:1138-1146.
42. U.S.Preventive Services Task Force Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2009, 151:784-792.
43. Al-Showair R.A., Tarsin W.Y., Assi K.H., et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respir Med 2007, 101:2395-2401.
44. Tashkin D.P., Pearle J., Iezzoni D., et al. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009, 6:17-25.
45. van Noord J.A., Aumann J.L., Janssens E., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26:214-222.
46. Karner C., Cates C.J. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012, 4. CD008989.
47. Wedzicha J.A., Calverley P.M., Seemungal T.A., et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177:19-26.
48. Aaron S.D., Vandemheen K.L., Fergusson D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146:545-555.
49. Calverley P.M., Rabe K.F., Goehring U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
50. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.
51. Rennard S.I., Anderson W., ZuWallack R., et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:1087-1092.
52. Mahler D.A., Donohue J.F., Barbee R.A., et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115:957-965.
53. O'Donnell D.E., Voduc N., Fitzpatrick M., et al. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004, 24:86-94.
54. Dahl R., Greefhorst L.A., Nowak D., et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:778-784.
55. Feldman G., Siler T., Prasad N., et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010, 10:11.
56. Kornmann O., Dahl R., Centanni S., et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011, 37:273-279.
57. Dahl R., Chung K.F., Buhl R., et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010, 65:473-479.
58. Donohue J.F., Fogarty C., Lotvall J., et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010, 182:155-162.
59. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003, 361:449-456.
60. Hanania N.A., Darken P., Horstman D., et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003, 124:834-843.
61. O'Donnell D.E., Sciurba F., Celli B., et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006, 130:647-656.
62. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21:74-81.
63. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
64. Ferguson G.T., Anzueto A., Fei R., et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008, 102:1099-1108.
65. Calverley P.M., Boonsawat W., Cseke Z., et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919.
66. Tashkin D.P., Rennard S.I., Martin P., et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008, 68:1975-2000.
67. Rennard S.I., Tashkin D.P., McElhattan J., et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009, 69:549-565.
68. Sin D.D., Tashkin D., Zhang X., et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009, 374:712-719.
69. Vincken W., van Noord J.A., Greefhorst A.P., et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002, 19:209-216.
70. Tashkin D.P., Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
71. Maltais F., Hamilton A., Marciniuk D., et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005, 128:1168-1178.
72. Kesten S., Casaburi R., Kukafka D., et al. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008, 3:127-136.
73. Murciano D., Auclair M.H., Pariente R., et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989, 320:1521-1525.
74. Zhou Y., Wang X., Zeng X., et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006, 11:603-610.
75. Barnes P.J. Emerging pharmacotherapies for COPD. Chest 2008, 134:1278-1286.
76. Ford P.A., Durham A.L., Russell R.E., et al. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010, 137:1338-1344.
77. Rabe K.F. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011, 163:53-67.
78. Rennard S.I., Calverley P.M., Goehring U.M., et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 2011, 12:18.
79. Martinez F.J., Curtis J.L., Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:331-350.
80. Peckham D.G. Macrolide antibiotics and cystic fibrosis. Thorax 2002, 57:189-190.
81. Seemungal T., Harper-Owen R., Bhowmik A., et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1618-1623.
82. Suzuki T., Yamaya M., Sekizawa K., et al. Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. Am J Respir Crit Care Med 2002, 165:1113-1118.
83. Banerjee D., Khair O.A., Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 2005, 99:208-215.
84. Suzuki T., Yanai M., Yamaya M., et al. Erythromycin and common cold in COPD. Chest 2001, 120:730-733.
85. Seemungal T.A., Wilkinson T.M., Hurst J.R., et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147.
86. Albert R.K., Connett J., Bailey W.C., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
87. Sethi S., Jones P.W., Theron M.S., et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010, 11:10.
88. Ries A.L., Make B.J., Lee S.M., et al. The effects of pulmonary rehabilitation in the national emphysema treatment trial. Chest 2005, 128:3799-3809.
89. Ries A.L., Kaplan R.M., Limberg T.M., et al. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995, 122:823-832.
90. Hui K.P., Hewitt A.B. A simple pulmonary rehabilitation program improves health outcomes and reduces hospital utilization in patients with COPD. Chest 2003, 124:94-97.